Ocugen stock surged 33% in extended trading as the WHO expert group will meet on Tuesday to approve EUA of COVID-19 vaccine covaxin in cooperation with India.
Ocugen shares are rising in the post-market ahead of a meeting by an advisory panel of The World Health Organisation (WHO) on Tuesday to discuss whether to grant an emergency use listing for its partner’s COVID-19 vaccine named Covaxin.
WHO will make a decision on the vaccine developed by Bharat Biotech based on the recommendations of the Technical Advisory Group.
Social media is abuzz with speculation that the WHO has already greenlighted the vaccine as the global body has posted on its website several documents related to the vaccine ahead of the meeting.
Ocugen (OCGN) partnered with Bharat Biotech to co-develop Covaxin for the U.S. market, and in late-stage trials, it has shown about 78% efficacy against COVID-19.
精彩评论